Hepatocellular Carcinoma
📧 Sign up to get email alerts when something new happens for Hepatocellular Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers [NA]
A pilot study comparing two ctDNA sampling methods (ctDNA IDV vs SPV) in patients undergoing biopsies for hepatobiliary and pancreatic cance…
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma [Phase 2]
A Phase 2 trial evaluating checkpoint inhibitors for pediatric hepatocellular carcinoma, including fibrolamellar hepatocellular carcinoma, i…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers [NA]
Clinical trial evaluating early multigene sequencing for theranostics in advanced cancers to guide therapy, across breast cancer, hepatocell…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: SBRT With Atezo/Bev for HCC [Phase 1]
Phase 1 clinical trial evaluating the combination of SBRT (stereotactic body radiotherapy) with atezolizumab and bevacizumab for hepatocellu…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes [NA]
Cedars-Sinai Medical Center is recruiting for a study evaluating virtual reality to manage gastrointestinal cancer pain and improve patient-…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma [Phase 1]
A Phase 1 study at MD Anderson Cancer Center is using 18F-FS PG PET imaging to guide therapy for hepatocellular carcinoma. The trial is curr…
-
CLINICAL_TRIALS withdrawal · 2026-02-19Clinical Trial Update: BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma [Phase 1, Phase 2]
Withdrawn Phase 1/2 clinical trial of BC3402 in combination with tremelimumab and durvalumab (STRIDE) for hepatocellular carcinoma.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Adjuvant TACE in HCC With High-risk Recurrence Factors [Phase 3]
Phase 3 trial evaluating adjuvant transarterial chemoembolization to reduce recurrence risk in hepatocellular carcinoma; recruitment is ongo…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies [Phase 1]
This clinical trial update describes a Phase 1/1B study of ST-01156, a small-molecule RBM39 degrader, in patients with advanced solid tumors…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation
This completed clinical trial evaluates the effect of pre-transplant tyrosine kinase inhibitors on outcomes, including survival, in hepatoce…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence [Phase 2]
A Phase 2 trial evaluating cadonilimab in hepatocellular carcinoma after radical surgery with high risk of recurrence has been terminated.
-
CLINICAL_TRIALS other · 2026-02-18Clinical Trial Update: Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC [Phase 2]
Phase 2 clinical trial evaluating durvalumab and tremelimumab in combination with Y-90 SIRT for intermediate-stage hepatocellular carcinoma …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Atezolizumab+Bevacizumab+SBRT in Unresectable HCC [Phase 1]
A Phase 1 clinical trial assessing a combination of atezolizumab, bevacizumab, and SBRT for unresectable hepatocellular carcinoma is current…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma [Phase 2]
Phase 2 clinical trial sponsored by the University of Florida evaluating an artificial intelligence–based drug-dosing approach for hepatocel…
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) [Phase 3]
This is a Phase 3 clinical trial update evaluating the combination of durvalumab and tremelimumab as first-line therapy for advanced hepatoc…
-
CLINICAL_TRIALS withdrawal · 2026-02-18Clinical Trial Update: Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment [Phase 1]
A Phase 1 study of NP-101 in patients with unresectable hepatocellular carcinoma undergoing Y-90 treatment has been withdrawn.
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning [NA]
This clinical trial aims to construct and clinically validate a predictive model using whole-slide digital pathology and deep learning to gu…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma [Phase 2]
A Phase 2 trial is investigating tislelizumab in combination with Huaier granule as first-line therapy for unresectable hepatocellular carci…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells [Phase 1]
Phase 1 pediatric trial of interleukin-15 and interleukin-21 armored glypican-3–specific CAR T cells for solid tumors, including liver-origi…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) [Phase 2]
Phase 2 RESCUE trial evaluating SHR-1210 (anti-PD-1) in combination with Apatinib for advanced hepatocellular carcinoma has completed and re…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients [Phase 1]
Phase 1 trial evaluating donafinib in combination with an anti-PD-1 antibody as adjuvant therapy for hepatocellular carcinoma has been compl…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Biobank for Cholestatic Liver Diseases.
Mayo Clinic is recruiting for a biobank study of cholestatic liver diseases, including primary sclerosing cholangitis and primary biliary ch…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab [Phase 3]
Phase 3 study evaluating atezolizumab plus lenvatinib or sorafenib versus lenvatinib or sorafenib alone in unresectable hepatocellular carci…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC [Phase 2]
A Phase 2 study evaluating Lenvatinib with Pembrolizumab, with or without branched-chain amino acids, for unresectable hepatocellular carcin…
-
CLINICAL_TRIALS other · 2026-02-17Clinical Trial Update: Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma
Clinical trial update indicates validation of blood-based biomarkers in hepatocellular carcinoma patients treated with transarterial chemoem…